EMA/PE/0000240529

Key facts

Active substance

• cagrilintide
• semaglutide

Therapeutic area

Metabolism and nutrition disorders

Decision number

EMA/PE/0000240529

PIP number

EMA/PE/0000240529

Pharmaceutical form(s)

Solution for injection

Condition(s) / indication(s)

Treatment of obesity

Route(s) of administration

Subcutaneous use

Contact for public enquiries

Novo Nordisk A/S

E-mail: [email protected] Tel.: +45 44448888

Decision type

PM: decision on the application for modification of an agreed PIP

Decision date

15/05/2025

Compliance check done

No

Decision

EMA/PE/0000240529 : EMA decision of 15 May 2025 on the acceptance of a modification of an agreed paediatric investigation plan for cagrilintide, semaglutide

Adopted

Reference Number:

EMADOC-1700519818-2117497

English (EN) (211.08 KB - PDF)

First published:

14/07/2026

View